Navigation Links
Boston Scientific Welcomes Launch of Syntax Score Website
Date:5/18/2009

larization option. The site also includes a detailed tutorial on the use of the SYNTAX Score calculator, including definitions and example cases, together with SYNTAX data presentations and publications.

"The SYNTAX Score website will be an important tool to assist with revascularization strategies in these complex patient populations," said Patrick W. Serruys, M.D., Ph.D., Chief of Interventional Cardiology, Thoraxcenter-Erasmus University, Rotterdam, The Netherlands, and chairman of the SYNTAX trial steering committee. "Having a consistent grading system for lesion complexity and severity of coronary artery disease allows me to better evaluate treatment options for my patients. The website's interactive calculator makes it easier to determine a patient's score and to reference current clinical data from the SYNTAX trial associated with that score."

The SYNTAX trial will continue to provide important data throughout the life of the trial (one-, three- and five-year outcomes). As more data become available, awareness and understanding of the SYNTAX trial will increase as will the utility of the SYNTAX Score.

"Boston Scientific is pleased to contribute the SYNTAX trial data to the advancement of evidence-based medicine," said Keith D. Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "The patients enrolled in SYNTAX have exceptionally complex anatomy and advanced disease, representing an unprecedented study group for a stent trial. Ongoing findings from this study will continue to be used to enhance the value of the SYNTAX Score in this high-risk patient population."

Boston Scientific will be announcing subset data analyses from the SYNTAX trial this week at EuroPCR.

The SYNTAX Score and SYNTAX Score website were developed under the direction of the SYNTAX trial steering committee, chaired by Dr. Serruys and F.W. Mohr, M.D., Ph.D., and were made po
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
2. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
3. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
4. Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University
5. UMass Boston Opens Venture Development Center to Expand R&D Activity
6. Boston Scientific Announces First Quarter Special Items
7. Boston Scientific Launches New Coronary Imaging Catheter
8. Moodys Raises Boston Scientifics Rating Outlook to Stable
9. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5
... against osteoporosis-related fractures, including spine and hip, - Reclast reduced ... to placebo in study published in New England Journal of Medicine, - Unique ... ... - Osteoporotic fractures affect one in two women over 50(1) and are ...
... a biotechnology company developing pharmaceutical products for use ... financing deal. The majority of the funding, $2.3 ... remainder was borrowed from the Madison Development Corporation, ... a private investment firm. The funds raised will ...
... the next strange idea you hear strange: the person ... door. , ,A panel of experienced entrepreneurs speaking ... Milwaukee last Wednesday have dealt with looks and whispers ... in the audience to accept the whispers as a ...
Cached Biology Technology:Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 2Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 3Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 4Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 5Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 6Quintessence Secures Financing 2Quintessence Secures Financing 3Lowering the fear factor for entrepreneurs, intra-preneurs 2Lowering the fear factor for entrepreneurs, intra-preneurs 3
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Education Association (SEA) is preparing to conduct the first-ever research ... debris in the North Atlantic Ocean. The ... 20-year data set previously collected by SEA that reveals a ... in the western North Atlantic Ocean. This trip ...
... from the University of Warwick has discovered taking too much ... your cholesterol by almost 10%. Selenium is a trace ... from foods such as vegetables, meat and seafood. However, when ... selenium, such as through taking selenium supplements, it can have ...
... , This release is available in French ... more than 3 times per week show a worse performance in ... of exposure to mercury show a generalised delay in cognitive, memory ... fish and canned fish and to a lesser extent in white ...
Cached Biology News:SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 2Too much selenium can increase your cholesterol 2Consumption of certain fish during pregnancy associated with poorer cognitive performance 2
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
... assay system offers the following ... for batch-processing systems, Long lasting ... microplates such as 384-well and ... storage conditions ( 2 - ...
... universal lysis buffer, PCR mix, DNA polymerase ... l volume PCR reactions. This system can ... positive rod and coccus bacteria, such as ... Aureus, Streptococcus Agalactiae, and etc. With the ...
... Staining Kit is uniquely formulated to ... minimal protein modification for optimal mass ... associated with traditional silver stains are ... the reagents used do not modify ...
Biology Products: